Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Cathrine Dawn Büttner Elgaard, Lars Iversen & Kasper Fjellhaugen Hjuler. (2023) Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. Journal of Dermatological Treatment 34:1.
Read now
Read now
Chuanlan Gu & Junyi Yang. (2019) Risankizumab for the treatment of psoriasis. Expert Review of Clinical Pharmacology 12:9, pages 851-857.
Read now
Read now
Articles from other publishers (29)
Xiaoying Sun, Liu Liu, Siting Chen, Jiao Wang, Xiaoce Cai, Jiankun Song, Mi Zhou, Dongjie Guo, Le Kuai, Xiaojie Ding, Bin Li & Xin Li. (2022) Fibrinogen-Like Protein 1 as a Novel Biomarker of Psoriasis Severity. Journal of Inflammation Research Volume 15, pages 4637-4647.
Crossref
Crossref
Holly Linley, Shafqat Jaigirdar, Karishma Mohamed, Christopher E. M. Griffiths & Amy Saunders. (2022) Reduced cutaneous CD200:CD200R1 signaling in psoriasis enhances neutrophil recruitment to skin. Immunity, Inflammation and Disease 10:7.
Crossref
Crossref
Tom Macleod, Charles Bridgewood, Isabel Hyde, Megan Heague, Philip Helliwell, Martin Stacey & Miriam Wittmann. (2022) Molecular and cellular regulation of psoriatic inflammation. Clinical Science 136:12, pages 935-952.
Crossref
Crossref
Amit Sharma, Deepak Kumar Upadhyay, Ghanshyam Das Gupta, Raj Kumar Narang & Vineet Kumar Rai. (2022) IL-23/Th17 Axis: A Potential Therapeutic Target of Psoriasis. Current Drug Research Reviews 14:1, pages 24-36.
Crossref
Crossref
Aina Akmal Mohd Noor, Maryam Azlan & Norhanani Mohd Redzwan. (2022) Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action. Biomedicines 10:2, pages 498.
Crossref
Crossref
Yeong Chae Ryu, Yoo Eun Lee & Byeong Hee Hwang. (2021) Efficient and safe small RNA delivery to macrophage using peptide‐based nanocomplex. Biotechnology and Bioengineering 119:2, pages 482-492.
Crossref
Crossref
Alison McFarlane, Paul K. Fyfe & Ignacio Moraga. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
37
64
.
Magdalena Kutwin, Monika Migdalska-Sęk, Ewa Brzeziańska-Lasota, Piotr Zelga & Anna Woźniacka. (2021) An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis. Journal of Clinical Medicine 10:24, pages 5834.
Crossref
Crossref
R. B. Warren, M. Lebwohl, H. Sofen, V. Piguet, M. Augustin, F. Brock, C. Arendt, F. Fierens & A. Blauvelt. (2021) Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. Journal of the European Academy of Dermatology and Venereology 35:12, pages 2398-2408.
Crossref
Crossref
Feras M. Ghazawi, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C. Wiseman, Charles Lynde & Ivan V. Litvinov. (2021) A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Frontiers in Medicine 8.
Crossref
Crossref
Anupriya Kapoor, Nikunj sethi & Navneet Verma. (2021)
Acitretin Loaded Nanocarrier Gel: Formulation and Exploration of
In-vitro
Release Kinetics
. Current Nanomedicine 11:2, pages 102-111.
Crossref
Crossref
Catherine C. Robertson, Jamie R. J. Inshaw, Suna Onengut-Gumuscu, Wei-Min Chen, David Flores Santa Cruz, Hanzhi Yang, Antony J. Cutler, Daniel J. M. Crouch, Emily Farber, S. Louis BridgesJrJr, Jeffrey C. Edberg, Robert P. Kimberly, Jane H. Buckner, Panos Deloukas, Jasmin Divers, Dana Dabelea, Jean M. Lawrence, Santica Marcovina, Amy S. Shah, Carla J. Greenbaum, Mark A. Atkinson, Peter K. Gregersen, Jorge R. Oksenberg, Flemming Pociot, Marian J. Rewers, Andrea K. Steck, David B. Dunger, Linda S. Wicker, Patrick Concannon, John A. Todd & Stephen S. Rich. (2021) Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. Nature Genetics 53:7, pages 962-971.
Crossref
Crossref
Youkyung S. Roh, Justin Choi, Nishadh Sutaria, Micah Belzberg, Madan M. Kwatra & Shawn G. Kwatra. (2021) IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses. Drugs 81:8, pages 895-905.
Crossref
Crossref
Robert Gironés Petit, Amanda Cano, Alba Ortiz, Marta Espina, Josefina Prat, Montserrat Muñoz, Patrícia Severino, Eliana B. Souto, Maria L. García, Montserrat Pujol & Elena Sánchez-López. (2021) Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. International Journal of Molecular Sciences 22:9, pages 4983.
Crossref
Crossref
Surjit Singh, Saurabh Singh, Abisha Thangaswamy, Pugazhenthan Thangaraju & Shoban Babu Varthya. (2020) Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis. Dermatologic Therapy 34:1.
Crossref
Crossref
Camila Cataldi de Alcantara, Edna Maria Vissoci Reiche & Andréa Name Colado Simão. 2021.
171
204
.
Juliana Santos Rosa Viegas, Fabíola Garcia Praça, Marcelo Kravicz & Maria Vitoria Lopes Badra Bentley. (2020) Therapeutic applications and delivery systems for triptolide. Drug Delivery and Translational Research 10:6, pages 1584-1600.
Crossref
Crossref
Vineet Kumar Rai, Priyam Sinha, Kuldeep Singh Yadav, Aparna Shukla, Archana Saxena, Dnyaneshwar Umrao Bawankule, Sudeep Tandon, Feroz Khan, Chandan Singh Chanotiya & Narayan Prasad Yadav. (2020) Anti-psoriatic effect of Lavandula angustifolia essential oil and its major components linalool and linalyl acetate. Journal of Ethnopharmacology 261, pages 113127.
Crossref
Crossref
Markus F. Neurath. (2020) IL-36 in chronic inflammation and cancer. Cytokine & Growth Factor Reviews 55, pages 70-79.
Crossref
Crossref
Iwona Adwent, Beniamin Oskar Grabarek, Marta Kojs-Mrożkiewicz, Ryszard Brus, Rafał Staszkiewicz, Andrzej Plewka, Michał Stasiowski & Anita Lyssek-Boroń. (2020)
The Influence of Adalimumab and Cyclosporine A on the Expression Profile of the Genes Related to TGF
β
Signaling Pathways in Keratinocyte Cells Treated with Lipopolysaccharide A
. Mediators of Inflammation 2020, pages 1-11.
Crossref
Crossref
Kristian Du Jardin, Pepi Lopez, Mette Lange, Rachael McCool, Silvia Naval & Sandra Quickert. (2020) A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab. Journal of Health Economics and Outcomes Research, pages 123-129.
Crossref
Crossref
Sobia Ahsan Halim, Ajmal Khan, Rene Csuk, Ahmed Al-Rawahi & Ahmed Al-Harrasi. (2020) Diterpenoids and Triterpenoids From Frankincense Are Excellent Anti-psoriatic Agents: An in silico Approach. Frontiers in Chemistry 8.
Crossref
Crossref
Chunlei Sun & Jianxin Xia. (2020) Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Medica 111:3.
Crossref
Crossref
Arlene Bravo & Arthur Kavanaugh. (2019) Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. Nature Reviews Rheumatology 15:11, pages 645-656.
Crossref
Crossref
Paul Scutt. (2019) From Evolution to Revolution: IL-23 in the Treatment of Psoriasis Patients. EMJ Dermatology, pages 71-78.
Crossref
Crossref
Ling-juan Zhang. (2019) Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis. Frontiers in Immunology 10.
Crossref
Crossref
Dominika Wcisło‐Dziadecka, Beniamin Grabarek, Celina Kruszniewska‐Rajs & Barbara Strzałka‐Mrozik. (2019) The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment. Dermatologic Therapy 32:3.
Crossref
Crossref
Simona-Roxana Georgescu, Mircea Tampa, Constantin Caruntu, Maria-Isabela Sarbu, Cristina-Iulia Mitran, Madalina-Irina Mitran, Clara Matei, Carolina Constantin & Monica Neagu. (2019) Advances in Understanding the Immunological Pathways in Psoriasis. International Journal of Molecular Sciences 20:3, pages 739.
Crossref
Crossref
Katja Škrlec, Petra Zadravec, Marie Hlavničková, Milan Kuchař, Lucie Vaňková, Hana Petroková, Lucie Křížová, Jiří Černý, Aleš Berlec & Petr Malý. (2018) p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin. International Journal of Molecular Sciences 19:7, pages 1933.
Crossref
Crossref